Evidence map›Paper›PMID 39314628›Full record

ArticleFrontiers in oncology2024

Overexpression of serum HMGB1 and IDO in esophageal squamous cell carcinoma patients: potential clinical auxiliary diagnostic markers and immunotherapeutic targets.

Wenxuan Cui, Yinghao Niu, Xueyuan Zhang, Beixuan Huang, Xiaoya Shang, Wei Zhao, Xi Yan, Yunqiang Mi, Ming Ma, Jinyan Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Alterations inContemporary oncology (Poznan, Poland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenxuan Cui *Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yinghao Niu *Department of Clinical Biobank, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xueyuan ZhangDepartment of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Beixuan HuangClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaoya ShangClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Wei ZhaoClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xi YanClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yunqiang MiClinical Laboratory, 984th Joint Logistic Support Force Hospital, Beijing, China.
Ming MaClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Jinyan ZhangClinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xingxiao YangDepartment of Infection Management, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High mobility group box 1 (HMGB1) and indoleamino-2, 3-dioxygenase (IDO) participate in the occurrence and development of esophageal squamous cell carcinoma (ESCC), regulate the tumor immune microenvironment, and are closely related to tumor growth and metastasis. However, the regulatory mechanism of serum HMGB1 and IDO has not been clarified and needs further exploration. Methods: Blood samples of 55 ESCC patients initially hospitalized in the Fourth Hospital of Hebei Medical University from August 2021 to January 2022 were selected as the ESCC group, and relevant clinical data were collected, and blood samples from 40 healthy people during the same period were selected as the control group. Serum HMGB1 and IDO levels were determined by ELISA, and lymphocyte subsets in peripheral blood of all subjects were detected by flow cytometry. The correlation between the expression levels of HMGB1 and IDO in ESCC cells was detected by Western blot. Results: Serum HMGB1 and IDO levels were significantly increased in ESCC patients, and with the progression of ESCC patients, serum HMGB1 and IDO levels were also gradually increased; serum HMGB1 was significantly correlated with IDO; serum HMGB1 and IDO combined with CEA and SCC-Ag were of high value in predicting the clinical progression of ESCC patients; the absolute counts of CD4 Conclusion: Serum HMGB1 and IDO have a synergistic effect, they inhibit immune function and promote tumor progression in ESCC patients, and also lead to poor prognosis.

Indexed as

ESCCHMGB1IDOlymphocyte subsetsprognosisserum

Identifiers

PMID39314628
PMCPMC11416914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.